A generic medicine indicated for viral infections. Inhibits the replication of viral cells within the bloodstream and reduces the viral load to address chronic infection markers.
Intended to relieve retroviral multiplication to support immune CD4 count preservation and target viral replicative enzymes.
Mechanism of Action
Efavirenz blocks reverse transcriptase non-competitively, while tenofovir and emtricitabine act as DNA chain terminators.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
24 hours
Contraindications
Severe renal impairment, Concurrent highly CYP3A4-dependent therapies, Hepatic failure
Severe Adverse Events
Lactic acidosis — requires immediate medical attention, Severe bone marrow suppression — requires immediate medical attention, Suicidal ideation — requires immediate medical attention
Common Side Effects
Dizziness, Headache, Insomnia
Uncommon Side Effects
Vivid dreams, Rash, Diarrhea
Drug Interactions
Rifampin, Simvastatin, St. John's Wort
Pregnancy Safety Warnings
TGA Category D: Avoid in first trimester. Discontinue breastfeeding to prevent transmission.
Age Restrictions
Approved for adults weighing over thirty-five kilograms.
Information related to Trustiva is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
